Point of Care Coagulation Testing Products Market Size - By Test Type (Prothrombin Time Testing Products, Activated Clotting Time (ACT/APTT) Testing Products), By Product Type– Global Forecast, 2023-2032

Point of Care Coagulation Testing Products Market Size

Point of Care Coagulation Testing Products Market size was valued at USD 2.3 billion in 2022 and is estimated to account for USD 4.8 billion by 2032. Point-of-care coagulation testing products are medical devices designed to rapidly assess blood clotting at the point of care, beyond traditional laboratory settings. They offer swift and accurate coagulation information, facilitating immediate clinical decisions during surgeries, emergencies, and ongoing chronic care. Global point of care testing industry is set to witness over 7% CAGR from 2023 to 2032 owing to the growing prevalence of multiple medical diseases across developing countries.
 

These portable devices utilize small blood samples to measure clotting parameters, assisting in treatment monitoring and disorder diagnosis. The industry is driven by factors such as rising chronic blood disorders, government initiatives, convenient testing, technology advancements, home healthcare growth, aging population, and improved healthcare infrastructure in emerging markets.
 

Chronic blood disorders, such as hemophilia and thrombophilia, have been on the rise due to various factors including genetic predisposition, lifestyle changes, and an aging population. For instance, in 2022, data from the World Bleeding Disorders Registry (WBDR) reported that among 11,374 individuals with hemophilia across 115 treatment centers in 44 countries, only 30% of adults and 32% of children with severe hemophilia received prophylactic treatment.
 

COVID-19 Impact

The COVID-19 pandemic brought about a significant and positive transformation in the industry, driven by a confluence of factors. For instance, according to a report from the British Medical Journal (BMJ), individuals with COVID-19 were potentially at a 33-fold greater danger of acquiring serious blood coagulates in their lungs within the first thirty days of infection. These products streamlined testing procedures, delivering quicker results and empowering medical professionals to make timely decisions, especially in critical care settings, and facilitated remote patients monitoring with chronic blood disorders.
 

Point of Care Coagulation Testing Products Market Trends

Governments globally prioritize early detection of blood-related diseases to reduce healthcare burdens, leading to a surge in initiatives including research funding, awareness campaigns, and subsidies for vital medical devices such as point of care coagulation testing products. For instance, in March 2022, the National Hemophilia Foundation launched the "Starts the Conversation" initiative for bleeding disorders awareness month. This initiative was designed to spotlight a diverse spectrum of experiences, encompassing disease conditions, research pursuits, educational endeavours, and advocacy efforts.
 

Furthermore, technological progress has yielded the creation of increasingly precise, dependable, and user-friendly point of care coagulation testing products. These advancements encompass refined sensors, automation, integration with electronic health records (EHRs), and seamless connectivity to smartphones or tablets. The heightened accuracy and simplified usage of these devices enhance healthcare providers' trust in their application.
 

Point of Care Coagulation Testing Products Market Analysis

The POC coagulation testing products market by test type is categorized into prothrombin time testing products, activated clotting time (ACT/APTT) testing products, and others. The prothrombin time testing products segment garnered USD 1.2 billion revenue size in the year 2022. The widely recognized importance of prothrombin time testing in anticoagulant therapy monitoring, bleeding risk assessment, and blood disorder management elevates its role. Furthermore, technological advancements, such as improved sensors and connectivity, have bolstered its accuracy and efficiency. Seamless integration with electronic health records (EHRs) and mobile devices has further improved its accessibility. Moreover, the segment's versatility across healthcare settings, from hospitals to home care, strengthens its appeal.
 

Based on product type, the point of care coagulation testing products market is segmented into instruments and consumables. The instruments segment accounted for over 63% market share in the year 2022 attributed to its fundamental role in ensuring accurate testing, coupled with advanced technological features. These instruments streamline testing procedures through automation and integration with electronic health records, enhancing efficiency and informed decision-making.
 

Moreover, their adaptability across various healthcare settings underscores their versatility. For instance, Sysmex has launched the automated blood coagulation analyzers CN-6500/CN-3500 in Japan. These analyzers employ the chemiluminescence enzyme immunoassay (CLEIA) principle, developed with HISCL, enabling flexible measurements for thrombosis and hemostasis tests, including molecular markers.
 

U.S. point of care coagulation testing products market accounted for USD 788 million revenue size in 2022. U.S. leadership is rooted by its robust healthcare infrastructure that fosters the integration of advanced medical technologies. The U.S.'s focus on preventive healthcare aligns well with the capabilities of point of care coagulation testing products, facilitating timely monitoring and management of blood disorders. Substantial investments in research and development have fuelled ongoing innovation in testing technology, resulting in products with heightened accuracy and efficiency.
 

For instance, according to the Centers for Disease Control and Prevention (CDC), the prevalence of hemophilia in the U.S. is observed in approximately 1 out of every 5,617 live male births. Furthermore, within the U.S., the population comprises an estimated 30,000 to 33,000 males living with hemophilia. Additionally, statistics indicate that between 60,000 to 100,000 Americans lose their lives due to deep vein thrombosis complications.
 

Point of Care Coagulation Testing Products Market Share

Some of the eminent industry participants operating in the point of care coagulation testing products market include
 

• Abbott Laboratories
• Helena Laboratories
• Thermo Fisher Scientific Inc
• Alere Inc.
• Medtronic plc
• Sysmex Corporation
• Diagnostica Stago Sas
• Nihon Kohden Corporation
• Micropoint Biosciences
• F. Hoffmann-La Roche Ltd.
   

Point of Care Coagulation Testing Products Industry News:

• In February 2021, Siemens Healthineers and Sysmex Corporation extended their global agreement for the supply, distribution, sales, and service of hemostasis products, encompassing Sysmex's CN-Series automated blood coagulation analyzers. This partnership brought advanced automated solutions for coagulation testing to laboratories, addressing mid and high-volume requirements. Furthermore, the extension of the agreement also included plans for Siemens Healthineers to initiate the distribution of Sysmex CN Systems in various countries in subsequent years.
   

Point of care coagulation testing products market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Test Type (USD Million & Units)

• Prothrombin time testing products
• Activated clotting time (ACT/APTT) testing products
• Others

By Product Type (USD Million)

• Instruments
• Consumables

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • The Netherlands
  • Denmark
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Thailand
  • Vietnam
  • Indonesia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Turkey